keyword
MENU ▼
Read by QxMD icon Read
search

Varithena

keyword
https://www.readbyqxmd.com/read/27013511/a-multicenter-randomized-placebo-controlled-study-to-evaluate-the-efficacy-and-safety-of-varithena%C3%A2-polidocanol-endovenous-microfoam-1-for-symptomatic-visible-varicose-veins-with-saphenofemoral-junction-incompetence
#1
Kathleen Gibson, Lowell Kabnick
OBJECTIVES: A randomized, placebo-controlled, multicenter study was conducted to evaluate the safety and efficacy of polidocanol endovenous microfoam (1%, Varithena® [polidocanol injectable foam], BTG International Ltd.). METHODS: Patients (n = 77) with symptomatic, visible varicose veins were randomized to treatment with either Varithena 1% or placebo. RESULTS: Varithena provided greater mean changes from Baseline in patient-reported assessments of symptoms (e...
March 24, 2016: Phlebology
https://www.readbyqxmd.com/read/26992303/durability-of-treatment-effect-with-polidocanol-endovenous-microfoam-on-varicose-vein-symptoms-and-appearance-vanish-2
#2
Kenneth L Todd, David I Wright
OBJECTIVE: The objectives of this study were to assess the durability of response to treatment with polidocanol endovenous microfoam (Varithena; Provensis Ltd, a BTG International group company) and to assess the long-term safety of the study patients. METHODS: This report presents efficacy and safety data from the day after visit 5/week 8 (the primary end point of the study) through the 1-year study visit. As the approved dose concentration is 1%, this analysis focuses on those patients who were randomized to polidocanol endovenous microfoam 1% at study visit 2...
July 2015: Journal of Vascular Surgery. Venous and Lymphatic Disorders
https://www.readbyqxmd.com/read/26957489/a-multicenter-randomized-placebo-controlled-trial-of-endovenous-thermal-ablation-with-or-without-polidocanol-endovenous-microfoam-treatment-in-patients-with-great-saphenous-vein-incompetence-and-visible-varicosities
#3
Michael Vasquez, Antonios P Gasparis
OBJECTIVES: *Varithena 017 Investigator Group: Michael Vasquez, MD, Venous Institute of Buffalo, Amherst, NY; Antonios Gasparis, MD, Stony Brook University Medical Center, Stony Brook, NY; Kathleen Gibson, MD, Lake Washington Vascular, Bellevue, WA; James Theodore King, MD, Vein Clinics of America, Oakbrook Terrace, IL; Nick Morrison, MD, Morrison Vein Institute, Scottsdale, AZ; Girish Munavalli, MD, Dermatology, Laser & Vein Specialists of the Carolinas, Charlotte, NC; Eulogio J. Sanchez, MD, Batey Cardiovascular Center, Bradenton, FL...
March 7, 2016: Phlebology
https://www.readbyqxmd.com/read/26449448/the-role-of-clinically-relevant-parameters-on-the-cohesiveness-of-sclerosing-foams-in-a-biomimetic-vein-model
#4
Dario Carugo, Dyan N Ankrett, Vincent O'Byrne, David D I Wright, Andrew L Lewis, Martyn Hill, Xunli Zhang
We have recently reported on the development of a biomimetic vein model to measure the performance of sclerosing foams. In this study we employed the model to compare the commercially-available Varithena(®) (polidocanol injectable foam) 1% varicose vein treatment (referred to as polidocanol endovenous microfoam, or PEM) with physician compounded foams (PCFs) made using different foam generation methods (Double Syringe System and Tessari methods) and different foam formulations [liquid to gas ratios of 1:3 or 1:7; gas mixtures composed of 100% CO2, various CO2:O2 mixtures and room air (RA)]...
November 2015: Journal of Materials Science. Materials in Medicine
https://www.readbyqxmd.com/read/26384639/treatment-of-truncal-incompetence-and-varicose-veins-with-a-single-administration-of-a-new-polidocanol-endovenous-microfoam-preparation-improves-symptoms-and-appearance
#5
RANDOMIZED CONTROLLED TRIAL
J T King, M O'Byrne, M Vasquez, D Wright
OBJECTIVE: This multicenter, parallel group study was designed to determine if a single administration of ≤15 mL of pharmaceutical-grade polidocanol endovenous microfoam (PEM, now approved in the United States as Varithena [polidocanol injectable foam], BTG International Ltd.) could alleviate symptoms and improve appearance of varicose veins in a typical population of patients with moderate to very severe symptoms of superficial venous incompetence and visible varicosities of the great saphenous vein (GSV) system...
December 2015: European Journal of Vascular and Endovascular Surgery
https://www.readbyqxmd.com/read/26218793/polidocanol-varithena-for-varicose-veins
#6
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
August 3, 2015: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/26036246/benefits-of-polidocanol-endovenous-microfoam-varithena%C3%A2-compared-with-physician-compounded-foams
#7
Dario Carugo, Dyan N Ankrett, Xuefeng Zhao, Xunli Zhang, Martyn Hill, Vincent O'Byrne, James Hoad, Mehreen Arif, David D I Wright, Andrew L Lewis
OBJECTIVE: To compare foam bubble size and bubble size distribution, stability, and degradation rate of commercially available polidocanol endovenous microfoam (Varithena®) and physician-compounded foams using a number of laboratory tests. METHODS: Foam properties of polidocanol endovenous microfoam and physician-compounded foams were measured and compared using a glass-plate method and a Sympatec QICPIC image analysis method to measure bubble size and bubble size distribution, Turbiscan™ LAB for foam half time and drainage and a novel biomimetic vein model to measure foam stability...
May 2016: Phlebology
https://www.readbyqxmd.com/read/24843085/endovenous-chemical-and-physical-treatments-for-varices-what-s-new
#8
Jean-Jérôme Guex
The constant evolution of endo-venous ablative techniques for varicose veins arises from the need for: better patient's comfort, reduced incidence of side effects, better results at short-, mid- and long-term follow-up, as well as reduction of operating time and technical simplicity. All these goals have been aimed at but so far no new technology has been able to achieve them all or to demonstrate it, furthermore the increase of price must be compensated by a considerable improvement of results and a serious reduction of side effects to be incrementally cost effective...
May 2014: Phlebology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"